AbCellera Biologics

Intangible assets: solid but still developing. AbCellera owns or exclusively licenses over 110 issued or allowed patents and 50+ pending applications, including foundational microfluidic single‑cell screening IP and the Trianni Mouse franchise, plus acquired/licensed technologies such as OrthoMab and TetraGenetics for GPCR/ion channel targets.

The Bruker settlement affirmed and monetized aspects of the microfluidic IP through an upfront and future royalties. These assets support differentiation, but many protections sunset in the 2030s and rivals also control strong toolsets. Switching costs: moderate and rising.

The company now spans discovery to early development and clinical manufacturing, which can embed methods, workflows, and data formats across multi‑year programs and create friction to switch vendors or platforms once candidates advance.

Still, partners can run parallel efforts with alternative platforms, so switching costs are not entrenched across the industry. Network effects and data: credible but unproven defensibility. Each new campaign expands internal datasets used by computational tools to improve candidate ranking across difficult targets (e.g., GPCRs).

The growing portfolio (104 program starts; 19 molecules in clinic) suggests improving selection funnels, yet we have limited hard evidence that data scale translates into sustainably better economics vs close competitors over a decade.

Cost advantage and efficient scale: integration and an in‑house clinical manufacturing site can accelerate timelines and reduce outsourcing costs for internal programs, but the field remains crowded with well‑funded tools companies and pharma internal platforms; there is no natural monopoly from scale alone.

Overall moat: multiple vectors developing, but durability still needs clinical proof points.